Hemostasis Diagnostics Market by Product Type (Systems, Consumables, Point-of-Care Testing Devices), By Test Type (Fibrinogen Test, Activated Clotting Time, Platelet Function, Prothrombin Time, Heparin & Protamine Dose-Response Test For ACT, Activated Partial Thromboplastin Time, Anti-Factor Xa, Other Coagulation Tests), By Technology (Optical, Mechanical, Electrochemical, Others), By End-User (Hospitals, Clinics, Diagnostic Centres, Others (POC)), and Geography (Latin America, North America, Asia Pacific, Middle East & Africa and Europe)

   

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

The global hemostasis diagnostics market size values USD 3.98 billion in 2021 and expected to reach USD 7.26 billion in 2028 at a CAGR of 9.1% during the forecast period 2022-2028. Hemostasis diagnostics are the devices used to determine the hemostatic defects, which cause excessive bleeding. Hemostasis is defined as stopping or slowing the blood flow from the damaged blood vessel. During the hemostasis, blood changes from liquid state to the gelatinous state. Hemostasis maintained in the body by three mechanisms namely, blood coagulation, platelet plug formation, and vasoconstriction. Hemostasis diagnostics may help to predict the cause of bleeding during surgery by identifying the hemostatic defects in patients. Different types of tests such as prothrombin test, activated clotting time, platelet function, and other coagulation tests are carried to identify the hemostasis defects. The market is growing at a significant rate due to rise in the prevalence of trauma condition and various surgeries around the globe. Moreover, the rise in prevalence of cardiovascular diseases, cancer, and diabetes also expected to propel the market. Furthermore, acquisitions and mergers, collaborations, test approvals, and launchings are the strategies followed by the companies for increasing their revenue share. For instance, in January 2017, Instrumentation Laboratory, a subsidiary of Werfen has acquired Accriva Diagnostics for the expansion of its hemostasis testing portfolio. In addition, in June 2017, Grifols and Beckman Coulter entered into a distribution agreement for the distribution of Grifol’s hemostasis instruments, consumables, and reagents around the globe.   Key Developments:  In November 2016, Siemens Healthineers launched CE-marked Atellica COAG 360 system, a high-volume specialty analyzer used in the hemostasis diagnostics

Hemostasis Diagnostics Market Summary

Study Period

2023-29

Base Year

2022

CAGR

9.1%

Largest Market

North America

Fastest Growing Market

Asia-Pacific
Hemostasis Diagnostics Market Dynamics

Increase in the incidence of blood clotting disorders such as haemophilia (according to National Hemophilia Foundation, approximately 400,000 incidences of haemophilia is observed in 2012), growing number of trauma patients and surgeries, and the introduction of biodegradable and cost-effective products are expected to propel the market growth over the forecast period. Moreover, technological advancements in the hemostasis diagnostics such as accurate results in less time, increase in awareness about the hemostasis diagnostics, and rise in R&D investment for novel tests and devices boost the market. However, the high cost of advanced hemostasis products and stringent regulations for the test approvals are expected to hamper the growth of market over the forecast period.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Hemostasis Diagnostics Market Segmentation

By Product Type
  • Systems
  • Consumables
  • Point-of-Care Testing Devices
By Test
  • Fibrinogen Test
  • Activated Clotting Time
  • Platelet Function
  • Prothrombin Time
  • Heparin & Protamine Dose-Response Test For ACT
  • Activated Partial Thromboplastin Time
  • Anti-Factor Xa
  • Other Coagulation Tests
By Technology
  • Optical
  • Mechanical
  • Electrochemical
  • Others
By End User
  • Hospitals
  • Clinics
  • Diagnostic Centres
  • Others (POC)

Frequently Asked Questions

The hemostasis diagnostics market is projected to expand at a CAGR of 9.1% during the forecast period    

Hoffmann-La Roche Ltd, Sysmex Corporation, Abbott Laboratories, Nihon Kohden Corporation, Siemens, Healthineers, Grifols S.A, Beckman Coulter, Inc.

North America is the fastest-growing region for the hemostasis diagnostics market

1. Executive Summary
2. Global Hemostasis Diagnostics Market Introduction
2.1. Global Hemostasis Diagnostics Market – Taxonomy
2.2. Global Hemostasis Diagnostics Market –Definitions
2.2.1. Product Type
2.2.2. Application
2.2.3. End User
3. Global Hemostasis Diagnostics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Hemostasis Diagnostics Market Dynamic Factors - Impact Analysis
3.6. Global Hemostasis Diagnostics Market – Competition Landscape
3.7. Epidemiology
4. Global Hemostasis Diagnostics Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028
4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Hemostasis Diagnostics Market, By Product Type, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.1. Laboratory Systems
5.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Consumables
5.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Point-of-Care Testing Systems
5.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Hemostasis Diagnostics Market Forecast, By Application, 2017 - 2021 and Forecast, 2022 - 2028
6.1. Activated Clotting Time
6.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Platelet Aggregation Test
6.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. D Dimer
6.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Fibrinogen Degradation Products (FDP)
6.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Activated Partial Thromboplastin Time (APTT)
6.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Prothrombin Test Time (PT)
6.6.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Others
6.7.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
7. Global Hemostasis Diagnostics Market Forecast, By End User, 2017 - 2021 and Forecast, 2022 - 2028
7.1. Hospital and Clinics
7.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Diagnostic Laboratories
7.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Hemostasis Diagnostics Market Forecast, By Region, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Hemostasis Diagnostics Market - Opportunity Analysis Index, By Product Type, Application, End User, and Region, 2022 - 2028
9. North America Hemostasis Diagnostics Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
9.1. By Product Type Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Laboratory Systems
9.1.2. Consumables
9.1.3. Point-of-Care Testing Systems
9.2. Application Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Activated Clotting Time
9.2.2. Platelet Aggregation Test
9.2.3. D Dimer
9.2.4. Fibrinogen Degradation Products (FDP)
9.2.5. Activated Partial Thromboplastin Time (APTT)
9.2.6. Prothrombin Test Time (PT)
9.2.7. Others
9.3. End User Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospital and Clinics
9.3.2. Diagnostic Laboratories
9.3.3. Others
9.4. Country Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Hemostasis Diagnostics Market - Opportunity Analysis Index, By Product Type, Application, End User, and Country, 2022 - 2028
9.6. North America Hemostasis Diagnostics Market Dynamics – Trends
10. Europe Hemostasis Diagnostics Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
10.1. By Product Type Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Laboratory Systems
10.1.2. Consumables
10.1.3. Point-of-Care Testing Systems
10.2. Application Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Activated Clotting Time
10.2.2. Platelet Aggregation Test
10.2.3. D Dimer
10.2.4. Fibrinogen Degradation Products (FDP)
10.2.5. Activated Partial Thromboplastin Time (APTT)
10.2.6. Prothrombin Test Time (PT)
10.2.7. Others
10.3. End User Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospital and Clinics
10.3.2. Diagnostic Laboratories
10.3.3. Others
10.4. Country Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Hemostasis Diagnostics Market - Opportunity Analysis Index, By Product Type, Application, End User, and Country, 2022 - 2028
10.6. Europe Hemostasis Diagnostics Market Dynamics – Trends
11. Asia-Pacific Hemostasis Diagnostics Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
11.1. By Product Type Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Laboratory Systems
11.1.2. Consumables
11.1.3. Point-of-Care Testing Systems
11.2. Application Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Activated Clotting Time
11.2.2. Platelet Aggregation Test
11.2.3. D Dimer
11.2.4. Fibrinogen Degradation Products (FDP)
11.2.5. Activated Partial Thromboplastin Time (APTT)
11.2.6. Prothrombin Test Time (PT)
11.2.7. Others
11.3. End User Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospital and Clinics
11.3.2. Diagnostic Laboratories
11.3.3. Others
11.4. Country Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Hemostasis Diagnostics Market - Opportunity Analysis Index, By Product Type, Application, End User, and Country, 2022 - 2028
11.6. Asia-Pacific Hemostasis Diagnostics Market Dynamics – Trends
12. Latin America Hemostasis Diagnostics Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
12.1. By Product Type Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Laboratory Systems
12.1.2. Consumables
12.1.3. Point-of-Care Testing Systems
12.2. Application Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Activated Clotting Time
12.2.2. Platelet Aggregation Test
12.2.3. D Dimer
12.2.4. Fibrinogen Degradation Products (FDP)
12.2.5. Activated Partial Thromboplastin Time (APTT)
12.2.6. Prothrombin Test Time (PT)
12.2.7. Others
12.3. End User Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospital and Clinics
12.3.2. Diagnostic Laboratories
12.3.3. Others
12.4. Country Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Hemostasis Diagnostics Market - Opportunity Analysis Index, By Product Type, Application, End User, and Country, 2022 - 2028
12.6. Latin America Hemostasis Diagnostics Market Dynamics – Trends
13. Middle East and Africa Hemostasis Diagnostics Market Analysis, 2017 - 2021 and Forecast, 2022 - 2028 (Revenue, USD Mn)
13.1. By Product Type Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Laboratory Systems
13.1.2. Consumables
13.1.3. Point-of-Care Testing Systems
13.2. Application Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Activated Clotting Time
13.2.2. Platelet Aggregation Test
13.2.3. D Dimer
13.2.4. Fibrinogen Degradation Products (FDP)
13.2.5. Activated Partial Thromboplastin Time (APTT)
13.2.6. Prothrombin Test Time (PT)
13.2.7. Others
13.3. End User Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospital and Clinics
13.3.2. Diagnostic Laboratories
13.3.3. Others
13.4. Country Analysis 2017 - 2021and Forecast 2022 - 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Hemostasis Diagnostics Market - Opportunity Analysis Index, By Product Type, Application, End User, and Country, 2022 - 2028
13.6. MEA Hemostasis Diagnostics Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Application & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Abbott Laboratories
14.2.2. Thermo Fisher Scientific, Inc.
14.2.3. F. Hoffmann-La Roche Ltd.
14.2.4. Nihon Kohden Corporation
14.2.5. Sysmex Corporation
14.2.6. Siemens Healthineers
14.2.7. Instrumentation Laboratory
14.2.8. Danaher Corporation
14.2.9. Grifols S.A
14.2.10. Alere, Inc.
15. Research Methodology
16. Key Assumptions and Acronyms
  • Hoffmann-La Roche Ltd. (Switzerland)
  • Sysmex Corporation (Japan)
  • Abbott Laboratories (U.S.)
  • Alere Inc.  (U.S.)
  • Nihon Kohden Corporation (Japan)
  • Siemens Healthineers (Germany)
  • Grifols S.A (Spain)
  • Beckman Coulter, Inc. (U.S.)